Cyteir Therapeutics
General Information | |
Business: | We are a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together. Our lead program, CYT-0851, as well as our next generation drug candidate CYT-1853, exploits a novel gain-of-function synthetically lethal relationship between overexpression of a family of DNA damaging genes called cytidine deaminases, or CDs, and functional inhibition of homologous recombination, or HR, a DNA repair pathway critical for the survival of some cancers. CYT-0851 is a novel, oral small molecule inhibitor of RAD51-mediated HR and, to our knowledge, is the only such inhibitor of RAD51-mediated HR in clinical development. (Note: Cyteir Therapeutics priced its IPO on June 17, 2021, at $18 – the top of its $16-to-$18 range – on 7.4 million shares, the same number as in the prospectus, to raise |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 31 |
Founded: | 2012 |
Contact Information | |
Address | 128 Spring St, Building A, Suite 510, Lexington, MA 02421, USA |
Phone Number | 857-285-4140 |
Web Address | http://www.cyteir.com |
View Prospectus: | Cyteir Therapeutics |
Financial Information | |
Market Cap | $585.99mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-22.2 mil (last 12 months) |
IPO Profile | |
Symbol | CYT |
Exchange | NASDAQ |
Shares (millions): | 7.4 |
Price range | $18.00 - $18.00 |
Est. $ Volume | $133.2 mil |
Manager / Joint Managers | J.P. Morgan/ Morgan Stanley/ BofA Securities |
CO-Managers | Wedbush Securities |
Expected To Trade: | 6/18/2021 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |